Company Description
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics.
It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery.
The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications.
It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.
The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.
Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Michael Rowe |
Contact Details
Address: 295 Madison Avenue, Suite 2400 New York, New York 10017 United States | |
| Phone | 833 393 6684 |
| Website | eyenovia.com |
Stock Details
| Ticker Symbol | EYEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682639 |
| CUSIP Number | 30234E104 |
| ISIN Number | US30234E1047 |
| Employer ID | 47-1178401 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael M. Rowe | Chief Executive Officer, President and Director |
| Dr. Tsontcho Ianchulev M.D., M.P.H., MPH | Co-Founder and Executive Director |
| Bren Kern | Chief Operating Officer and Corporate Vice President |
| John P. Gandolfo CPA | Secretary |
| Andrew D. Jones | Chief Financial Officer, Secretary and Treasurer |
| Tony Cardinale | Vice President of Sales |
| Norbert Lowe | Senior Vice President of Commercial Operations |
| Alexander Lobo | Investor Contact |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 8, 2024 | EFFECT | Notice of Effectiveness |
| Oct 4, 2024 | UPLOAD | Filing |
| Oct 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 30, 2024 | 8-K | Current Report |